InspireMD, Inc.

NSPR Healthcare Medical Devices

InspireMD, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.0 million, up 28.1% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 34.6% and free cash flow fell 26.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

0.46 0.02 −4.17%
Market cap
$22.3M
P/E
0.0×
Fwd P/E
−2.5×
Dividend yield
—
F-score
5/9
Altman Z
−2.61
Beneish M
−3.55
Dividend safety
n/a

InspireMD, Inc. (NSPR) EV/Sales

Alert me on EV/Sales

As of 16 October 2026, InspireMD, Inc. (NSPR) trades at a EV/Sales of 1.1×. Over the past ten years it has ranged from −5.4× (May 2021) to 7,252,565× (January 2015); the current reading is higher than 53% of that period. That is below the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 7.1× (37.02%)
FY2024 11.3× 130.33%
FY2023 4.9× —
FY2022 −1.3× —
FY2021 −1.8× —
FY2020 −0.5× —
FY2019 0.1× —
FY2018 −0.5× —
FY2017 0.6× (50.45%)
FY2016 1.3× 50.57%

Quarterly newest first

Period EV/Sales Change
Jun 2026 3.0× (66.96%)
Mar 2026 9.1× 27.65%
Dec 2025 7.1× (52.73%)
Sep 2025 15.1× 6.47%
42 more quarters

Against its own ten years

Low −5.4× High 7,252,565×
Ten-year median 0.9×
Current reading's percentile 35

EV/Sales against peers

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on NSPR